Strontium causes osteomalacia in chronic renal failure rats  by Schrooten, Iris et al.
Strontium causes osteomalacia in chronic renal failure rats
IRIS SCHROOTEN, WALTER CABRERA, WILLIAM G. GOODMAN, SIMONNE DAUWE, LUDWIG V. LAMBERTS,
RITA MARYNISSEN, WALTER DORRINE´, MARC E. DE BROE, and PATRICK C. D’HAESE
Departments of Nephrology and Chemistry, University of Antwerp, Belgium, and Department of Radiology Science, UCLA, Los Angeles,
California, USA
Strontium causes osteomalacia in chronic renal failure rats.
Background. We recently reported an association between
increased bone strontium (Sr) levels and osteomalacia in dialysis
patients.
Methods. To delineate whether or not Sr acts as a causal factor
in the development of osteomalacia, we devised the following
study: four groups of chronic renal failure (CRF) rats were given
Sr, aluminum (Al), both of these compounds or none of the
elements (controls).
Results. Administration of Sr and/or Al resulted in increased
bone levels of the respective elements. Histological examination
revealed impairment of mineralization in the Sr group and to a
lesser extent in the Al group as compared to the control group.
There was also a significant increase in osteoid area in the Sr
group, but not in the Al group. No differences in bone surface or
erodic perimeter were noted between the various study groups.
Histochemically, Sr could be localized in calcified bone, mainly in
new bone close to the osteoid/calcification front, a critical site of
bone mineralization. Histochemical findings were confirmed by
electron probe X-ray microanalysis.
Conclusions. These findings indicate that Sr accumulation in
chronic renal failure rats resulted in the development of osteo-
malacic lesions, in contrast to the Al group where adynamic bone
disease was induced in the present set-up. Further studies are
required to define the mechanism by which way Sr causes
osteomalacia in chronic renal failure rats.
Patients on chronic maintenance dialysis usually develop
some type of renal osteodystrophy, either hyperparathy-
roidism, adynamic bone disease, osteomalacia or a mixed
lesion. In addition, because of the impaired renal function,
the medication and the use of contaminated parenteral
fluids, trace elements may accumulate in dialysis patients.
An association between bone aluminum (Al) accumulation
and the development of osteomalacia and to a lesser extent
adynamic bone disease has repeatedly been established
[1–3]. Aside from Al, much less is known about the effects
of other trace metals on bone metabolism in dialysis
patients.
In a recent multicenter study, histological/chemical ex-
amination of 100 bone biopsies of dialysis patients present-
ing the various types of renal osteodystrophy revealed bone
strontium (Sr) levels, as well as Sr/calcium (Ca) ratios to be
increased in osteomalacic patients. Bone Sr levels were not
only elevated compared to individuals with a normal bone
histology, but also in comparison to all other types of renal
osteodystrophy [4].
Like Al and Ca, Sr is a ‘bone-seeking’ element 99% of its
total body burden being stored in bone [5]. Sr exhibits a
number of physicochemical similarities with Ca and there-
fore has been used as a reliable index for Ca-absorption [6].
In previous experiments an important influence of Sr on Ca
homeostasis [7] has been postulated, as well as interactions
with vitamin D synthesis [8] and bone metabolism [9], two
processes that are disturbed in chronic renal failure. In
experimental studies in rats and mice with intact renal
function a dose-dependent effect of Sr on different param-
eters of bone metabolism has been demonstrated. Low
doses of Sr stimulate bone formation [9] and increase bone
mass [10], while high Sr doses induce hypomineralization
[10] and transiently inhibit bone resorption [11, 12]. Fur-
thermore, in vitamin D3-repleted chicks it has been shown
that by inhibiting both the synthesis of 1,25-dihydroxychole-
calciferol and intestinal Ca absorption, dietary Sr can
induce rickets, reflected by a diminished growth and an
improper bone mineralization, histological features highly
comparable to these of osteomalacia [8]. Recently, an
epidemiological study in Turkey demonstrated a signifi-
cantly higher prevalence of the clinical diagnosis of rickets
in children living in a region with a high soil Sr content and
where nutrition was mainly based on cereals, compared to
that in children living in a low Sr region [13].
Although Rudolph, Alfrey and Smythe [14] made the
interesting suggestion in 1973 that Sr could play a role in
renal osteodystrophy in the dialysis patient, to the best of
our knowledge we are the first to demonstrate an associa-
tion between increased bone Sr levels in dialysis patients
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and the presence of a particular type of renal osteodystro-
phy, that is, osteomalacia [4]. These epidemiological data,
however, do not allow us to conclude whether Sr played a
causative or contributive role in the development of the
bone disease. Here we report data from a study in rats
demonstrating a causal role of Sr in the development of
osteomalacia in chronic renal failure.
METHODS
Experimental design
Using the remnant kidney model, chronic renal failure
was induced in 32 female Wistar rats at eight weeks of age.
Under sodium pentobarbital anesthesia (60 mg/kg) two
branches of the renal artery of the right kidney were ligated
and two weeks later the left kidney was removed. Four
weeks after nephrectomy rats were divided into four
groups: 8 controls, 8 rats loaded with Sr (Sr), 8 loaded with
Al (Al) and 8 animals loaded with both Sr and Al (Sr1Al).
In all groups except for the Sr-group, one rat died after
induction of the chronic renal failure. Sr loading was done
seven days/week by adding SrCl2 z 6H2O at a concentration
of 10.0 g/liter (0.34% Sr) to the animals’ drinking water, as
previously described [9, 10, 15]. Aluminum loading was
done orally six days/week by addition of 400 mg of Al(OH)3
to 40 g of rat chow and addition of 10 mg/liter of AlCl3 to
the drinking water. On day 7 a solution containing 17.9 mg
AlCl3 z 6H2O and 15.6 mg citrate in 500 ml saline (0.9%),
pH 6 5 was injected intraperitoneally. Control and Sr-
loaded rats received on the same day an intraperitoneal
injection of 15.6 mg citrate dissolved in 500 ml saline
(0.9%), pH 6 5. Food and drink administered to the Sr
groups was checked for the presence of Al and vice versa.
Rats were pair fed and weighed weekly. Animals had free
access to food and water. Water as well as food consump-
tion were recorded daily. The loading protocol was contin-
ued over 12 weeks. The rats were sacrificed the day
following the end of the loading protocol. At five and two
days before sacrifice, respectively demeclocyclin (30 mg/kg)
and tetracycline z HCl (30 mg/kg) labeling were performed.
At regular times during the loading period, blood and urine
samples were taken and frozen at 280°C until analysis (Fig.
1). For urine collection the animals were housed individu-
ally in metabolic cages and 24 hour urine samples were
collected. Blood was collected from the tail vein during the
loading period and by cardiac puncture at sacrifice under
ether anesthesia. Bone was removed at sacrifice and stored
at 220°C until analysis.
Biochemical and chemical determinations
Creatinine in serum and urine was determined according
to the Jaffe´ method. iPTH in serum was determined using
the INS-PTH kit (Incstar Corp., Stillwater, MN, USA),
validated for the analysis of rat serum [16].
Sr and Al in serum, urine, and bone were analyzed using
a Zeeman 3030 atomic absorption spectrometer equipped
with an HGA-600 graphite furnace, an AS-60 autosampler
and an Anadex DP-9500B silent scribe printer, all from
Perkin-Elmer (Norwalk, CT, USA). To determine Sr,
serum samples were diluted fourfold in a 0.5 ml/liter Triton
X-100 to 1 ml/liter HNO3 solution, whereas urine samples
were diluted 1:20 with HNO3. Bone samples were digested
with concentrated HNO3 in stoppered polytetrafluoroeth-
ylene (Teflon®) tubes [17]. Al in serum was determined
after 1:3 dilution of the samples in RO-water while urine
samples were diluted in a mixture of RO-water and acetic
acid. To measure Al in bone, the same digestion procedure
as the one used for Sr was used. Interassay CVs were ,6%
(N 5 6) and the recovery of added analyte was close to
100% for the determination of Sr and Al in the various
biological matrices under study. All material coming in
contact with the samples were tested as potential sources of
Fig. 1. Detailed time scheme of the experimental rat study. Abbreviations
are: B, blood sampling for creatinine, Al, Sr, Ca, P, and iPTH; U, urine
sampling for creatinine, Al, Sr, and Ca.
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Sr and/or Al. Material showing detectable Al (1 mg/liter or
more) or Sr (3 mg/liter or more) after a five-day contact
with doubly distilled water and nitric acid (10%) were
discarded. The use of glassware was avoided and only
doubly distilled water was used for sample preparation.
Methods for the determination of Sr and Al have been
described by us in detail previously [17–19]. Ca and P in
serum were determined with a Vitros 750 XRC spectro-
photometer in the Laboratory of Biochemistry of the
University Hospital of Antwerp. Ca determinations in urine
and bone were done by flame-AAS (Mod. 3110; Perkin-
Elmer) after diluting the samples 1:500 in RO-water to
which 1 g/liter lanthane was added to avoid ionization-
interferences.
Bone histology
At sacrifice, femurs and tibiae were freed of soft tissue.
From each rat one bone sample was, after removal of skin
and muscle tissue, weighed immediately and stored at
220°C until bulk analysis with AAS. The second sample,
which was used for histological examination, was fixed for
24 hours in Burkhardt solution and then transferred to a
70% ethanol solution. Longitudinal sections (4 mm) of the
proximal tibia were cut with a Jung K microtome and
stained with toluidine blue. Histological examination and
classification were done at the UCLA School of Medicine
(W. Goodman). Bone histological data as well as dynamic
parameters are reported using standardized nomenclature
and definitions [20, 21]. The parameters measured include:
total bone area [B. Ar (%); the area of trabecular bone,
including both mineralized bone and osteoid, expressed as
a percentage of the total tissue area], osteoid area [O. Ar
(%); the measured area of osteoid expressed as a percent of
the total bone area], osteoid thickness [O. Th (mm); the
mean width of surface osteoid seams, calculated by dividing
the measured osteoid area by the length of the osteoid
seams], osteoid perimeter [O. Pm (%); perimeter occupied
by osteoid, minimum width specified for the measurement
of osteoid surface], eroded surface [E. Pm (%); the per-
centage of trabecular bone surface characterized by the
presence of scalloped bone resorptive lacunae], double
labeled surface [dLS (%); percentage of total endosteal
surface exhibiting a double fluorescent tetracycline label],
mineral apposition rate [MAR (mm/day); distance between
the midpoints or between the corresponding edges of two
consecutive tetracycline labels, divided by the time interval
between the labeling periods], mineralization lag time
[MLT (days); mean time interval between deposition and
mineralization of any infinitesimal volume of matrix, aver-
aged over the entire lifespan of the osteoid seam] and bone
formation rate [BFR (mm2/mm2/day); volume of bone
formed per unit of time, calculated as the product of
mineral apposition rate and mineralizing surface].
Localization of strontium
Histochemically Sr could be demonstrated by modifica-
tion of a method described by Waterhouse [22]. This
method is based on a specific chelation of Sr by sodium
rhodizonate under the formation of a reddish-brown color.
Using this method, originally developed for the staining of
Sr in insects, the element could be demonstrated on
histological sections of bone provided the pH was lowered
from 5.5 to 3.5, by using an acetate buffer instead of the
conventional phosphate buffer and at a temperature of 0°C
instead of at room temperature.
Sr was also demonstrated microanalytically by electron
probe X-ray microanalysis (EPXMA). For this purpose,
100-mm thick carbon coated histological sections of rat
bone samples embedded in glycol-methylmethacrylate were
analyzed with a Jeol JSM 6300 (Jeol, Tokyo, Japan).
Statistics
All results are expressed as mean 6 SD. Statisitical
analysis of the data was done using the one way ANOVA
followed by the Bonferroni correction when more than two
groups were considered. A P value , 0.05 was considered
to be significant at a two-tailed level.
RESULTS
Biochemical and chemical data
The daily food and water consumption did not differ
between the four groups under study, resulting in compa-
rable weights at sacrifice. Comparison of serum creatinine
levels before induction of CRF and at sacrifice using the
remnant kidney model indicates that a moderate degree of
renal failure was induced (Table 1). As also indicated in
Table 1, urine output was comparable at start of loading
and at sacrifice among the various study groups. There was
a tendency for the intracellular parathyroid hormone
(iPTH) to increase during the loading period in all groups,
which, however, was not significant. Serum Ca and P
concentrations at start of loading were within the normal
range in all groups and had not changed by the time of
sacrifice (Table 1). At sacrifice, urinary Ca excretion was
significantly elevated in the Sr and Sr/Al group (Table 1).
Sr, Al and Ca concentrations in bone of the different
groups are presented in Table 2. Loading of the animals
with Sr, Al or the combination of both elements led to a
significant accumulation of these in the respective groups.
In order to correct for bone density, we also determined the
Ca concentration in bone. The bone Ca content did not
differ between the groups under study. Hence, the Sr/Ca
and Al/Ca ratios showed the same trend as noted for the
absolute concentrations. As for bone, serum Sr and Al
concentrations were also significantly higher in the groups
loaded with these elements (Table 2).
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Histological data
Figure 2 shows a Goldner staining of a control (Fig. 2a),
a Sr-loaded (Fig. 2b) and an Al-loaded rat (Fig. 2c). The
increased amount of osteoid in the Sr-loaded animal doc-
uments osteomalacia. By contrast, Goldner staining of the
rat loaded with Al shows that the amount of osteoid is
comparable to that in the controls.
There was no difference in bone area between all groups
(Fig. 3A). The osteoid area, however, was clearly increased
in the Sr group, compared to the control animals and the
group that received only Al (Fig. 3B). The mean osteoid
area in the Sr/Al group was comparable to that of the Sr
group, though there was substantial individual variation. A
comparable trend was observed in the osteoid perimeter
(Fig. 3C) and osteoid thickness (Fig. 3D). The histomor-
phometric parameters reflecting mineralization, namely
dLS, MAR, BFR and MLT, also differed from the control
group. Both dLS (Fig. 3E) and MAR (Fig. 3F) in the Sr and
Sr/Al loaded animals were approximately one-fourth the
values seen in the controls. Intermediate values were noted
for the Al group. A similar trend was noted for the BFR
(Fig. 3G). The MLT (Fig. 3H) was clearly increased in the
three groups, which were loaded with Sr, Al or both of
these elements. No significant differences in eroded surface
were found (Fig. 3I), which indicates the absence of an
effect on bone resorption from either of the two toxins.
Localization of strontium
Rhodizonate staining histochemically localized Sr in
calcified bone, mainly in new formed bone in close prox-
imity to the mineralization front and surrounding the
osteoid. In a control rat staining was negative (Fig. 4).
Histochemical findings were confirmed by EPXMA. By
using this technique the element could also be demon-
strated in calcified bone near the mineralization front (Fig.
5).
DISCUSSION
As we previously reported, in a histological/chemical
survey of 100 bone biopsies from dialysis patients coming
from several centers in various countries, increased Sr
concentrations as well as Sr/Ca ratios were observed in the
bone of patients suffering from osteomalacia as compared
to all other types of renal osteodystrophy [4]. Although the
prevalence of osteomalacia has decreased in the overall
dialysis population, the disease is still frequently observed
in less developed countries. In this context it is of interest
that we only found increased bone Sr concentrations in
patients living in these countries. This was confirmed in a
second epidemiological study where increased serum Sr
concentrations were also only found in patients living in
these regions. Hence, for these individuals strontium tox-
icity may be a serious potential problem. To which extent
Table 1. Biochemical parameters in serum and urine of the various study groups
Controls Sr Al Sr/Al
Serum creatinine mg/dl Pre-CRF (week 0) 0.98 6 0.64 0.86 6 0.42 0.62 6 0.26 0.77 6 0.11
At sacrifice 1.36 6 0.27 1.60 6 0.52 1.36 6 0.10 1.49 6 0.31
Serum Ca mg/dl Start loading (week 6) 10.35 6 0.30 10.45 6 0.69 10.54 6 0.19 9.91 6 0.29
At sacrifice 10.20 6 0.43 10.69 6 0.39 10.77 6 0.72 11.42 6 0.69
Serum P mg/dl Start loading (week 6) 6.14 6 0.73 6.84 6 1.29 4.70 6 0.81 5.70 6 0.80
At sacrifice 5.38 6 0.85 5.61 6 1.72 4.75 6 0.67 5.03 6 1.53
Urinary Ca mg/mg creatinine Start loading (week 6) 20.18 6 12.04 17.54 6 11.19 11.61 6 8.04 26.29 6 15.57
At sacrifice 8.92 6 4.83a 47.31 6 27.13a,b 20.87 6 22.39 67.40 6 25.94a,b
Urine ml Start loading (week 6) 22 6 6 22 6 5 16 6 3 16 6 5
At sacrifice 20 6 5 29 6 8 22 6 7 25 6 5a
Abbreviations are: Sr, strontium; Al, aluminum; Ca, calcium; P, phosphorus.
a P , 0.05 vs. pre-loading; b P , 0.05 vs. C
Table 2. Serum and bone Sr and Al concentrations, bone Ca concentrations and Sr/Ca and Al/Ca ratios
Controls Sr Al Sr/Al
Bone Sr mg/g 0.027 6 0.004 3.521 6 0.888 0.032 6 0.017 3.332 6 0.954
Bone Al mg/g 2.10 6 1.90 1.10 6 0.40 26.3 6 7.90 36.3 6 13.6
Bone Ca mg/g 191 6 19 183 6 15 177 6 8.3 172 6 14
Bone Sr/Ca 3103 0.14 6 0.01 22.0 6 5.80 0.19 6 0.10 22.7 6 9.87
Bone Al/Ca 3106 11.0 6 10.4 6.92 6 2.51 156 6 46.3 259 6 134
Serum Sr mg/liter Start loading (week 6) 0.021 6 0.006 0.024 6 0.005 0.018 6 0.002 0.021 6 0.008
At sacrifice 0.028 6 0.011 33.24 6 8.25 0.035 6 0.008 28.88 6 7.82
Serum Al mg/liter Start loading (week 6) 3.0 6 3.6 1.0 6 0.0 1.0 6 0.0 11 6 8.9
At sacrifice 2.0 6 1.6 3.0 6 1.2 14 6 7.3 16 6 5.6
Abbreviations are in Table 1.
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the water purification system, with or without a reverse
osmosis system, the use of contaminated concentrates, or
the diet play a role in the Sr accumulation in dialysis
patients has not yet been shown [23]. The fact that most Sr
present in the body is being eliminated by the kidney may
also contribute to its accumulation in dialysis patients [24].
The experiments described in this paper were designed
to assess the role of Sr in the development of osteomalacia
in dialysis patients. The remnant kidney rat model was
used, which is well recognized to be a suitable method to
induce a moderate, stable chronic renal failure in animals.
Loading of the rats was done over a relatively long period.
This relatively long loading protocol resembles the actual
chronic accumulation of trace elements in dialysis patients.
Data from the present study for the first time demonstrate
that Sr can cause osteomalacia. Based on a pilot study and
other reports [9, 10, 15], relatively high amounts of Sr were
used in the present experiment to correct for the relatively
higher bone turnover and glomerular filtration rate in rats
compared to humans, which would protect the rats against
accumulation of Sr and its deleterious effects.
No differences in iPTH values were observed between
the different groups nor did the iPTH significantly increase
after induction of chronic renal failure. This agrees with
previous reports that iPTH elevation occurs after at least 20
weeks in this model [25]. Comparison of the iPTH levels
between Sr loaded animals and the control group further
shows that the element seems not to influence iPTH
secretion. This is a controversial point that is in agreement
with some prior studies [26] and disagreement with others
[27, 28]. No data are available on the effect of Sr on the
synthesis of iPTH.
Although no differences in serum Ca concentrations
were observed between the different groups, urinary Ca
was increased in the rats loaded with Sr. This was noted in
the absence of any difference in urinary volumes, excluding
that the enhanced urinary Ca excretion could be due to
diuresis. Since high concentrations of Sr have been de-
scribed to decrease Ca absorption either directly or indi-
rectly through the element’s interference with vitamin D
biosynthesis [8], and because no differences in serum Ca
levels were observed between the different groups, it is
highly unlikely that the increased urinary output was due to
an increased Ca absorption in the treated groups. In view of
the above, we suggest that the observed increment might
result from a delayed or reduced incorporation of Ca in
bone secondary to Sr accumulation. Also, the incorportion
of Sr in bone has been shown to be accompanied by a mild
distortion of the crystal lattice, which in turn leads to an
increased bone mineral solubility and thus a lower bone
mineral density [29], which consequently may result in an
enhanced efflux of Ca from bone and thus an increased
urinary Ca excretion. Although no data exist, Sr might also
inhibit tubular reabsoption of Ca.
Histological analysis clearly show an increased amount of
Fig. 2. Goldner staining of a control (a), a Sr-loaded (b) and an
Al-loaded rat (c). Note the increased amounts of osteoid in the Sr-loaded
animal and the absence of osteoid in the Al-loaded rat.
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Fig. 3. Histological data of the various groups. *P , 0.05; **P , 0.01; ***P , 0.001.
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osteoid in rats of the Sr-group, as compared to the controls
and Al-loaded animals. The decreased bone formation and
increased MLT (the time it takes for osteoid to mineralize)
document dynamically the impairment of mineralization. A
defective mineralization in combination with an increased
osteoid volume are two major characteristics of osteoma-
lacia. Hence, the lesions we describe in rats loaded with Sr
have histological features of typical osteomalacia [20, 30].
In rats loaded with Al the degree of mineralization was
also decreased, though osteoid volume was not increased.
Since in this group the amount of osteoid was comparable
to that in the control animals, these rats actually developed
Fig. 4. (left) Histochemical analysis of a histological bone section of a
Sr-loaded rat. (a) Rhodizonate staining demonstrates the presence of Sr
at the osteoid/calcification front (3 81). (b) Magnification (3202.5) clearly
demonstrates the presence of small consecutive lines. (c) Schematic
summary of the histochemical result.
Fig. 5. (right) Electron probe X-ray microanalysis of a histological bone
section of a Sr-loaded rat. (a) Ca (white) is homogeneously present in
calcified bone. (b) Sr (yellow) could be demonstrated in calcified bone,
with most of the Sr present near the mineralization front. (c) Schematic
summary of the EPXMA analysis.
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an adynamic bone disease. This pathology, characterized by
a decreased mineralization in the absence of an increased
osteoid, suggests an effect on osteoblast activity rather than
on mineralization. Our findings agree with studies per-
formed in rats with normal renal function. In these rats Al
administration led to a decrease in bone and matrix forma-
tion that was not accompanied by an increase in osteoid
[31, 32]. In another study in which Al was administered to
both normal rats and rats with chronic renal failure,
osteomalacia was induced. In that study, however, Al was
administered at a dose that was almost twofold higher than
the one we used [2].
In the group of animals loaded with both Sr and Al some
rats developed adynamic bone disease, whereas in others
osteomalacia occurred. To which extent the development
of the latter bone disease is aggravated by the concerted
accumulation of both elements cannot be deduced from
our data. This observation, together with the fact that
Al-loaded rats in our study developed only adynamic bone
disease, suggests that the so-called “Al-induced osteoma-
lacia” in dialysis patients might not solely be due to Al, but
could be the result of a multi-element effect. In this respect,
epidemiological findings of our multicenter study demon-
strating a good correlation between Al and Sr in the
osteomalacic patients but not in those presenting the other
types of renal osteodystrophy is of particular interest [4]. In
previous studies, Rudolph et al [14] and Canavese et al [33]
also made the suggestion that in addition to Al, Sr might
play a role in the development of renal osteodystrophy in
dialysis patients.
The fact that we could not observe any differences
between the Sr groups and controls in the eroded surface,
which is an indirect measure of bone resorption, indicates
the absence of an effect of Sr on bone resorption under the
conditions of the present study. Other studies in both rats
and mice with normal renal function demonstrated an
inhibition of bone resorption by Sr [11, 12].
Localization of Sr was done by a modification of the
method of Waterhouse [22] using Na-rhodizonate, a histo-
chemical staining technique that was initially developed to
demonstrate Sr in soft tissues. Modification of this method
permits identification of Sr in bone when present at high
enough concentrations. Histochemical staining of Sr
showed the presence of the element in mineralized bone,
mainly at the region of the osteoid/calcification front, thus
in newly forming bone. The presence of Sr at this site may
point to a possible interference of the element with bone
mineralization. By using electron probe X-ray microanaly-
sis (EPXMA), a technique that detects X-rays generated by
an electron beam, the histochemical observations could be
confirmed. Scarce data in literature based on X-ray micro-
analysis have also demonstrated the presence of Sr in
mineralized bone, mainly present in newly formed bone
[15].
A preferential deposition of Sr at the osteoid/calcifica-
tion front is similar to the deposition of Al in bone noted in
dialysis patients with either osteomalacia or adynamic bone
disease. Deposition at the osteoid/calcification front of
both elements, however, is different: whereas in the case of
Al usually one line is demonstrated histochemically, stain-
ing for Sr shows a series of parallel lines.
When comparing both elements, not only a different
pattern of deposition is seen, but the mechanisms of Sr and
Al effects on bone are also different. Aluminum seems to
have a direct as well as indirect effect, through the inhibi-
tion of iPTH on the osteoblast, which results in a defective
osteoblast function [34]. Our data and those of others
indicate that Sr affects mineralization in the presence of an
active osteoblast and does not inhibit iPTH [11, 26].
In conclusion, Sr loading can induce osteomalacia in a
chronic renal failure rat model. In contrast to Sr, Al loading
results in the development of adynamic bone disease.
Histochemically and by means of electron microscopy, Sr is
localized in mineralized bone, mainly at the osteoid/calci-
fication front. Our data point to a causative role for Sr in
the development of osteomalacia. The mechanism by which
Sr induces this bone disease is not yet known.
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APPENDIX
Abbreviations used in this article are: Al, aluminum; B. Ar, total bone
area; BFR, bone formation rate; Ca, calcium; CRF, chronic renal failure;
dLS, double labeled surface; E. Pm, eroded surface; EPXMA, electron
probe X-ray microanalysis; iPTH, intact parathyroid hormone; MAR,
mineral apposition rate; MLT, mineralization lag time; O. Ar, osteoid
area; O. Th, osteoid thickness; Sr, strontium.
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